The impact of antithrombin III supplementation on prognosis during extracorporeal membrane oxygenation: a systematic review and meta-analysis

Overall, AT III supplementation does not reduce in-hospital mortality, bleeding, or thrombotic complications in ECMO patients and may even pose risks in certain populations. Therefore, routine AT III supplementation in ECMO patients may be not currently recommended.